Indictment of the microglia as the villain in multiple sclerosis

Neurology

Volumn 48, Issue 2, 1997, Pages 464-470

  Sriram, S ^a,c   Rodriguez, M ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c MS Research Lab   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD45 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE ANTIGEN; T LYMPHOCYTE RECEPTOR;

ALLERGIC ENCEPHALITIS; ARTICLE; AUTOIMMUNITY; DEMYELINATING DISEASE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; MACROPHAGE; MICROGLIA; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0031019547     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.48.2.464     Document Type: Article

References (69)

1. Martin R, McFarland HF, McFarlin DE. Immunology of demyelinating disease. Annu Rev Immunol 1992;10:153-169.
2. McDonald WI. Rachelle Rishman-Matthew Moore lecture. The pathological and clinical dynamics of MS. J Neuropathol Exp Med 1994;53:338-343.
3. Kurtzke JF. Epidemiologic evidence for MS as an infection. Clin Microbiol Rev 1993;6:382-427.
4. Raine CS. The Dale McFarlin memorial lecture. The immunology of the MS lesion. Ann Neurol 1994;36:S61-S72.
5. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell mediated autoimmunity: viral peptides activate human T cell clones specific for MBP. Cell 1995;80:695-705.
6. Marrack P, Kappler JW. Subversion of the immune system by pathogens. Cell 1994;76:323-332.
7. Steinman L. Escape from "horror autoxicus": pathogenesis and treatment of autoimmune disease. Cell 1995;80:7-10.
8. Scolding NJ, Zajicek JP, Compston DAS. The pathogenesis of demyelinating disease. Prog Neurobiol 1994;43:143-173.
9. Owens T, Sriram S. The immunology of MS and its animal model, EAE. Neurol Clin North Am 1995;13:51-73.
10. Prineas JW. The neuropathology of acute MS lesion. Handbood Clin Neurol 1985;3:213-257.
11. Esiri MM, Reading MC. Macrophage population associated with MS plaques. Neuropathol Appl Neurobiol 1987;13:451-468.
12. Cross AH, Cannella B, Brosnan CF, Raine C. Homing to CNS bt antigen specific lymphocytes. Localization of 14C labelled cells in acute and chronic EAE. Lab Invest 1990;63:162.
13. Waksman BH. Evidence favouring delayed sensitization as a mechanism underlying EAE. In: Kies M, Alvord EC, eds. Allergic encephalitis. Springfield: Charles C Thomas, 1959:419-443.
14. Raine CS. Multiple sclerosis: immunopathological mechanisms in the progression and resolution of inflammatory demyelination. Res Publ Assoc Res Nerv Ment Dis 1990;68:37-54.
15. Dawson JW. Histology of MS. Trans R Soc Edinburgh 1916;L: 517-740.
16. Raine CS. A pivotal role for T cells in MS lesion development. Neuropathol Appl Neurobiol 1991;17:265-305.
17. Adams RD, Kubik CS. The morbid anatomy of demyelinating disease. Am J Med 1952;12:510-546.
18. Lumsden CE. Pathology of MS and allied demyelinating disease. In: McAlpine D, Compston ND, Lumsden CE, eds. Multiple sclerosis. Edinburgh: Livingstone, 1955:208-293.
19. Seitelberger F. Pathology of MS. Ann Clin Res 1973;5:337-344.
20. Guseo A, Jellinger K. The significance of perivascular infiltration in MS. J Neurol 1975;211:51-60.
21. Nesbit GM, Forbes GS, Scheithauer BW, Okazaki H, Rodriguez M. MS: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology 1991;180:467-474.
22. Rodriguez M, Scheithauer B. Ultrastructure of multiple sclerosis. Ultrastruct Pathol 1994;18:3-13.
23. Rodriguez M, Scheithauer BW, Forbes G, Kelly PJ. Oligodendrocyte injury is an early event in lesions of multiple sclerosis. Mayo Clin Proc 1993;68:627-636.
24. Griffin DE, Moser HW, Mendoza Q, Moench TR, O'Toole S, Moser AB. The identification of inflammatory cells in the CNS of patients with adrenoleukodystrophy. Ann Neurol 1985;18: 660-666.
25. Powers JM, Liu Y, Moser AB, Moser HW. The inflammatory myelinopathy of ALD: cells effector molecules and pathogenetic implications. J Neuropathol Exp Neurol 1992;51:630-643.
26. Moser HW, Naidu S, Kumar AJ, Rosenbaum AE. Adrenoleukodystrophy. Crit Rev Neurobiol 1987;3:28-88.
27. Hayashi T, Morimoto C, Burks JS, Hauser S. Dual labelled immunocytochemistry of the active MS lesions: MHC and activation antigens. Ann Neurol 1988;24:523-530.
28. Sobel RA. T lymphocyte subsets in MS lesions. Res Immunol 1989;140:208-222.
29. Acha-Orbea H, Mitchell DJ, Timmerman L, et al. Limited heterogeneity of T cell receptors from lymphocytes mediating EAE allows specific immune intervention. Cell 1988;54:263-273.
30. Oksenberg JR, Stuart S. Begonovich AB, et al. Limited heterogeneity of rearranged T cell receptor Vα transcripts in brains of MS patients. Nature 1990;345:344-349.
31. Oksenberg JR, Panzara MA, Steinman L. Multiple sclerosis: from immunogenetics to immunotherapy. J Neurol Sci 1993; 115(suppl):29-37.
32. Shimonkevitz R, Colburn C, Burnham J, Murray RS, Kotzin BL. Clonal expansion of activated gamma/delta T cells in recent onset multiple sclerosis. Proc Natl Acad Sci USA 1993;90: 923-927.
33. Wucherpfennig KW, Newcombe J, Kebby C, Cuzner ML, Hafler DA. Gamma/delta T cell receptor repertoire in acute demyelinating multiple sclerosis lesions. Proc Natl Acad Sci USA 1992;89:4588-4592.
34. Sobel RA, Kuchroo VK. The immunopathology of acute experimental allergic encephalomyelitis induced with myelin proteolipid protein. T cell receptors in inflammatory lesions. J Immunol 1992;149:1444-1451.
35. Rajan AJ, Gao YL, Raine CS, Brosnan CF. A pathogenic role for yδ T cells in relapsing-remitting experimental allergic encephalomyelitis in the SJL mouse. J Immunol 1996;157:941-949.
36. McDonald WI. The significance of optic neuritis. Trans Ophthal Soc (UK) 1983;103:230-246.
37. Chou YK, Bourdette DN, Offner H, et al. Frequency of T cells specific for MBP and PLP in blood and CSF in patients with MS. J Neuroimmunol 1992;38:105-114.
38. Allegretta M, Nicklas JA, Sriram S, Albertinio RJ. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 1990;247:718-721.
39. Lodge AP, Johnson C, Sriram S. Frequency of MBP and MBP peptide-reactive T cells in the HPRT mutant T-cell population of MS patients. Neurology 1996;46:1410-1415.
40. Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner H, Hafler DA. Increased frequency of IL2 responsive T cell specific MBP and PLP in peripheral blood and CSF of patients with MS. J Exp Med 1994;179:973-984.
41. Sriram S, Roberts CA. Treatment of established chronic relapsing experimental allergic encephalomyelitis with anti-L3T4 antibodies. J Immunol 1986;136:4464-4469.
42. Sriram S, Carroll L, Fortin S, Cooper S, Ranges G. In vivo immunomodulation by monoclonal anti-CD4 antibody. II. Effect on T cell response to myelin basic protein and experimental allergic encephalomyelitis. J Immunol 1988;141:464-468.
43. Steinman L. Multiple sclerosis and its animal models: the role of the major histocompatibility complex and the T cell receptor repertoire. Semin Immunopathol 1992;14:79-93.
44. Cyclosporine Study Group. Efficacy and toxicity of cyclosporine in chronic progressive MS: a randomized double blind placebo controlled clinical trial. Ann Neurol 1990;27:592-605.
45. Weinshenker BG, Bass B, Karlik S, Ebers GC, Rice GPA. An open trial of OKT3 in patients with MS. Neurology 1991;41: 1047-1051.
46. Lindsey JW, Hodgkinson S, Mehta R, Mitchell D, Enzmann D, Steinman L. Repeated treatment with chimeric anti CD4 antibody in MS. Ann Neurol 1994;36:183-188.
47. Barkhof F, Thompson AJ, Hodgkinson S, Oeston BV, Lai M, Polman C. Double blind placebo controlled MRI monitored trial of chimeric anti CD4 antibodies in MS. J Neuroimmunol 1995;S1:15.
48. Berger JR, Sheramata WA, Resnik L. MS like illness occurring in patients with HIV infection. Neurology 1989;39:324-329.
49. Nepom GT, Erlich H. MHC class II molecules and autoimmunity. Ann Rev Immunol 1991;9:393-426.
50. Perry VH, Gordon S. Macrophages and the nervous system. Int Rev Cytol 1991;125:203-244.
51. Scolding NJ, Compston DAS. Oligodendrocyte macrophage interaction in vitro triggered by specific antibodies. Immunology 1991;72:127-132.
52. Renno T, Krakowski M, Piccirillo C, Owens T. TNF alpha expression by resident microglial and infiltrating leukocytes in the central nervous system of mice with EAE. J Immunol 1995;154:944-953.
53. Tansey FA, Brosnan CF. Protection against EAE by silica quartz dust. J Neuroimmunol 1982;3:169-179.
54. Brosnan CF, Bornstein MB, Bloom BR. Effect of macrophage depletion on the clinical and pathologic expression of EAE. J Immunol 1982;126:614-620.
55. Huitinga I, Rooijen NV, Groot CJD, Uitdehaag BMJ, Dijkstra CD. Suppression of EAE in Lewis rats after elimination of macrophages. J Exp Med 1990;172:1025-1033.
56. Rodriguez M, Quddus J. Effect of cyclosporin A, silica quartz dust, and protease inhibitors on virus-induced demyelination. J Neuroimmunol 1986;13:159-174.
57. Selgelid R, Eskeland T. The biology of the macrophage. Eur J Haematol 1993;51:267-275.
58. Lindholm PF, Reid RL, Brady JN. Extracellular Tax1 stimulates TNF and immunoglobulin kappa light chain in lymphoid cells. J Virol 1992;66:1294-1302.
59. Dhib-Jalbut S, Hoffman PM, Yamabe T, et al. Extracellular human T cell lymphotropic type 1 Tax protein induces cytokine production in adult human microglial cells. Ann Neurol 1994;36:787-790.
60. Meda L, Cassatella MA, Szendrei GI, et al. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 1995;374:647-650.
61. Chiang CS, Powell HC, Gold LH, Samimi A, Campbell IL. Macrophage/microglial-mediated primary demyelination and motor disease induced by the central nervous system production of interleukin-3 in transgenic mice. J Clin Invest 1996;97: 1512-1524.
62. Taupin V, Renno T, Krakowski M, Antel J, Peterson A, Owens T. Transgenic mice producing TNFα and IFN gamma in CNS. Presented at the 6th International TNF Congress, European Cytokine Network, 1996:156-316.
63. Budka H. Neuropathology of human immunodeficiency virus infection. Brain Pathol 1991;1:163-175.
64. Gray F, Scaravilli F, Everall I, et al. Neuropathology of early HIV-1 infection. Brain Pathol 1996;6:1-15.
65. Amlie-Lefond C, Kleinschmidt-DeMasters BK, Mahalingam R, Davis LE, Gilden DH. The vasculopathy of varicella-zoster virus encephalitis. Ann Neurol 1995;37:784-790.
66. Swoveland PT, Johnson KP. SSPE and other paramyxovirus infections. Handbook Clin Neurol 1989;12:417-423.
67. Walker WS. Origins of macrophage diversity: functional and phenotypic analysis of cloned populations of mouse splenic macrophages. Cell Immunol 1987;107:417-432.
68. Ulvestad E, Williams K, Mork S, Antel J, Nyland H. Phenotypic differences between human monocytes/macrophages and microglial cells studied in situ and in vivo. J Neuropathol Exp Neurol 1994;53:492-501.
69. Walker W, Gatewood J, Olivas E, Askew D, Havenith CE. Mouse microglial cell lines differing in constitutive and interferon-gamma inducible activities for maive and memory CD4+ and CD8+ T cells. J Neuroimmunol 1995;63:163-174.